Novartis takes on UK NHS
The UK's National Health System has cut the cost of treating wet age-related macular degeneration (AMD) by prescribing a cheaper
drug over a more expensive one. The controversial element is that the cheaper drug isn't licensed for wet AMD, which has prompted
anger from Novartis.
Merck job cuts
Merck KGaA has revealed further details about its restructuring programme, including plans to eliminate around 580 jobs. A
further 750 positions will be transferred from Switzerland to alternative sites mainly in Germany, the US and China. Among
other actions, the company will close its Merck Serono headquarters in Geneva.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new anticounterfeiting strategy with the
aim of curbing the occurrence of falsified medicines in the county's supply chain. The strategy will focus on prevention,
incident management, and investigation of all reports of falsified medicines in the UK.
GSK eyes medicines class
GlaxoSmithKline has partnered with the US's Yale university to design a new class of medicines that could be beneficial in
areas such as oncology and infection. The collaboration will use proteolysis targeting chimeric molecules, which have the
ability to guide proteins to a cell's cleaning mechanism, where they can then be destroyed.